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Abstract Aims/hypothesis: The exact pathogenesis of
retinopathy in diabetic and non-diabetic individuals is in-
completely understood, but may involve chronic low-grade
inflammation and dysfunction of the vascular endothelium.
The aim of this study was to investigate the association of
inflammation and endothelial dysfunction with prevalent
retinopathy in individuals with and without type 2 diabe-
tes. Methods: As part of a population-based cohort study,
625 individuals aged 50–74 years, stratified according to
age, sex and glucose tolerance status, underwent an exten-
sive physical examination. Retinopathy was assessed by
an ophthalmological examination, including funduscopy and
two-field 45° fundus photography with mydriasis in both
eyes. Levels of C-reactive protein (CRP), soluble intercel-
lular adhesion molecule-1 (sICAM-1), von Willebrand fac-
tor, and soluble vascular adhesion molecule-1 (sVCAM-1)
were assessed, together with the urinary albumin : creati-
nine ratio, and the results were combined to obtain summa-
rising z scores for inflammation and endothelial dysfunction.
Results: The prevalence of retinopathywas positively asso-
ciated with tertiles of CRP and sICAM-1. When compared
with the lowest tertile, the highest tertile of the inflamma-
tory z score was associated with retinopathy in all subjects
(odds ratio [OR]=2.2, 95% CI 1.2–4.1, adjusted for age,
sex and glucose tolerance status). The highest tertile of
the endothelial dysfunction z score was associated with
retinopathy among diabetic individuals (OR=4.4, 95% CI
1.2–15.9, adjusted for age and sex) but not in non-diabetic
individuals. Additional adjustment for other risk factors,
such as systolic and diastolic blood pressure, BMI, total
cholesterol and triglycerides, or mutual adjustment of the
inflammatory and endothelial dysfunction z scores did not
change the results. Conclusions/interpretation: In this study,
inflammatory activity and endothelial dysfunction were
associated with retinopathy, which suggests their involve-
ment in the pathogenesis of retinopathy.
Keywords Endothelial dysfunction . Inflammation .
Retinopathy . Type 2 diabetes
Abbreviations ACR: albumin:creatinine ratio . CRP:
C-reactive protein . IGM: impaired glucose metabolism .
NGM: normal glucose metabolism . OR: odds ratio .
sICAM-1: soluble intercellular adhesion molecule-1 .
sVCAM-1: soluble vascular adhesion molecule-1 .
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Introduction
Hyperglycaemia, diabetes duration, hypertension, dyslip-
idaemia and obesity are important risk factors for the
development and progression of diabetic retinopathy [1–3].
However, the exact pathogenesis of diabetic retinopathy
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remains unclear. Inflammation and endothelial dysfunction
are possible mechanisms, and these may play an important
role in the aetiology of diabetic retinopathy [4].
Markers of inflammation and endothelial dysfunction,
such as C-reactive protein (CRP), soluble intercellular adhe-
sion molecule-1 (sICAM-1), soluble vascular cell adhesion
molecule-1 (sVCAM-1) and von Willebrand factor (vWf),
have been associated with macroangiopathy in non-diabetic
individuals and in those with type 2 diabetes [5–9]. With
respect to microangiopathy, inflammation and endothelial
dysfunction have been associated with the development of
microalbuminuria [10, 11], which itself is strongly asso-
ciated with retinopathy in type 1 and type 2 diabetes [12–
14]. Furthermore, levels of sICAM-1 and sVCAM-1 have
been reported to be elevated in subjects with diabetic ret-
inopathy [15–17]. Taken together, these observations raise
the question of whether inflammation and endothelial dys-
function are involved in the pathogenesis of retinopathy.
To our knowledge, the associations of inflammation and
endothelial dysfunction with retinopathy have never been
investigated in a population-based study. The aim of the
present study was to investigate the associations of inflam-
mation (estimated by levels of CRP and sICAM-1) and
endothelial dysfunction (estimated by levels of vWf and
sVCAM-1 and the urinary albumin:creatinine ratio [ACR]),
with retinopathy.
Subjects and methods
Study design The Hoorn Study is a cohort study of type
2 diabetes and cardiovascular complications in a 50- to
74-year-old general Caucasian population, which started
in 1989 (n=2484, response rate 71%) and has already been
extensively described [18]. All subjects, apart from those
previously diagnosed with diabetes who were being treated
with oral glucose-lowering agents or insulin, underwent
an OGTT. All diabetic patients and all persons with a 2-h
post-load glucose concentration ≥7.5 mmol/l, as well as
an age- and sex-stratified random sample of persons with
a 2-h post-load glucose concentration of <7.5 mmol/l,
were invited within 4 weeks of their first visit for a sec-
ond visit to investigate complications related to glucose
intolerance (of 709 invited, 631 [89%] participated) [18].
These subjects underwent a second OGTT (apart from
those who already used blood-glucose-lowering agents
[n=67]). Using the mean value of two OGTTs, patients
were divided into three categories on the basis of glucose
tolerance: normal glucose metabolism (NGM; n=258), im-
paired glucose metabolism (IGM; n=179) or type 2 dia-
betes (n=192). The diagnoses were made according to the
criteria adopted by the World Health Organization in 1999
(NGM: fasting plasma glucose <7.0 mmol/l and 2-h post-
load plasma glucose <7.8 mmol/l; IGM: fasting plasma
glucose <7.0 mmol/l and 2-h post-load plasma glucose 7.8–
11.1; type 2 diabetes: fasting plasma glucose ≥7.0 mmol/l
or 2-h post-load plasma glucose ≥11.1 mmol/l) [19]. Sub-
jects treated with oral glucose-lowering agents, insulin or
diet were classified as having known diabetes. The sam-
pling method used was chosen for reasons of efficiency,
because we wished to study a small, but still random,
sample in more detail. As the exact sampling procedure is
known, we can back-calculate the prevalences in the initial
cohort (n=2484) from those in the smaller sample (n=631),
as previously described in detail [18, 20]. Written informed
consent was obtained from all participants. The Ethical
Review Committee of the VU University Medical Centre
(Amsterdam, the Netherlands) approved the Hoorn Study.
Ophthalmological examination At baseline, the retina was
examined with funduscopy and/or fundus photography
after mydriasis with eye drops containing 0.5% tropic-
amide and 5% phenylephrine. This ophthalmological exam-
ination has been extensively described previously [1]. Briefly,
funduscopy reports and/or fundus photographs were ob-
tained from 626 participants. The fundus photographs of
148 persons were lost (not associated with age, sex, glucose
tolerance category, blood pressure or worst eye visual acu-
ity; data not shown). For one person, both photographs were
not gradable and the funduscopy report was incomplete.
Thus, 625 individuals were included for further analyses.
All photographs (11×11 cm) were re-graded for retinopathy
according to the EURODIAB standards [1]. The EURO-
DIAB classification schemewas used because this uses two-
field 45° fundus photography and standard photographs to
grade retinal lesions [21]. Retinopathy was defined as the
presence of one or more microaneurysms, haemorrhages,
hard exudates, areas of neovascularisation, fibrous prolif-
eration and/or laser coagulation scars in at least one eye.
Minimal non-proliferative retinopathy (EURODIABgrade 1)
was diagnosed using fundus photography [21]. In each
subject the ‘worst’ eye was graded for retinopathy using
fundus photography or funduscopy.
Markers of endothelial dysfunction and inflammation
Concentrations of CRP, sICAM-1, vWf and sVCAM-1
were assessed in frozen (−70°C), heparinised samples of
plasma. The mean duration of storage was 8.3 years (range
7.3– 9.4 years). Because of a lack of spare plasma, values
for CRP, vWf and sVCAM-1 are missing for 21 subjects
and values for sICAM-1 are missing for 23 subjects. The
assessment of sVCAM-1, vWf, CRP and sICAM-1 has
previously been described [5, 6, 22]. Microalbuminuria
was defined as an ACR of 2.0–30.0 mg/mmol in an early-
morning, first-voided spot urine sample [23]. In a random
sample of 174 subjects, the ACR was based on the mean
of two measurements [23]. In this study the ACR was used
as a continuous measure of urinary albumin excretion.
Additional measurements We measured HbA1c, blood
pressure, total cholesterol, HDL cholesterol, triglycerides,
homocysteine, weight, height and body circumference, as
described previously [18, 24]. Subjects with a diastolic
blood pressure ≥90 mmHg, a systolic blood pressure ≥140
mmHg and/or using antihypertensive medication were con-
sidered to have hypertension [25]. The Rose questionnaire
was used to determine the subjects’ history of cardiovas-
cular disease [18].
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Statistical analyses Results are presented as means±SD,
percentages or, in the case of a skewed distribution, as
medians with interquartile ranges. Correlations between the
independent variables CRP, sICAM-1, vWf and sVCAM-1
were studied and calculated using the partial correlation
coefficient.
To create a more robust estimate for inflammation and
endothelial dysfunction, we constructed a summarising
score for each entity by adding the individual markers to-
gether. To this end, an individual z score for every marker of
inflammation and endothelial dysfunction was assessed for
each subject as follows: (individual value−the mean value
for the study population)/standard deviation. Because the
regression coefficients of the individual z scores were not
significantly different from each other (p values>0.05), sum-
marising scores could be created. The summarising score
for inflammation was calculated as (z score for CRP+z score
for sICAM-1)/2. Similarly, we constructed a summarising
score for endothelial dysfunction using z scores for vWf,
sVCAM-1 and ACR (used as a continuous marker of uri-
nary albumin excretion). Compared with the individual
markers, both summarising scores improved the fit of the
model (p<0.05). Because sVCAM-1 and sICAM-1 may be
markers of both inflammation and endothelial dysfunction,
we constructed two other scores for inflammation and en-
dothelial dysfunction, including sICAM-1 and sVCAM-1
in both scores.
Logistic regression analyses were used to assess the risk
of retinopathy associated with baseline variables and mark-
ers of inflammation and endothelial dysfunction. Because
there was a non-linear relationship between retinopathy and
CRP, sICAM-1, vWf, sVCAM-1, urinary ACR, and the
summarising scores for inflammatory activity and endo-
thelial dysfunction, tertiles were constructed for these var-
iables, with the lowest tertile used as the reference category.
Because of the sampling procedure used, we first adjusted
for age, sex and glucose tolerance status (stratification var-
iables), using two dummy variables for age, one for sex and
three for glucose tolerance status (for IGM, newly di-
agnosed diabetes and known diabetes) [18] (crude model).
We also adjusted for potential confounders (adjusted mod-
el), i.e. variables significantly associated with retinopathy
(Table 1). We did not include HbA1c in the multivariate
model because it is likely that hyperglycaemia causes en-
dothelial dysfunction and inflammation, which means that
analyses adjusted for HbA1c are probably overadjusted to a
certain extent. Furthermore, we did not consider micro-
albuminuria as a potential confounder, as it was already
included in the z score for endothelial dysfunction.
Table 1 Baseline characteristics of the participants according to retinopathy status
No retinopathy (n=540) Retinopathy (n=85) Difference in risk factor or indicator OR (95% CI)
Sex (% male) 49 40 Male vs female 0.74 (0.46–1.19)
Age (years) 64±7 65±7 Per 5-year increase 1.03 (0.87–1.22)
IGM (%) 32 28 Versus normal glucose metabolism 1.23 (0.66–2.31)
Type 2 diabetes (%) 28 48 Versus normal glucose metabolism 2.33 (1.46–3.73)
HbA1c (%) 5.80±1.20 6.66±1.76 Per 1% increase 1.28 (1.07–1.53)
Hypertension (%) 55 67 Yes vs no 1.22 (0.72–2.06)
Systolic blood pressure (mmHg) 138±19 147±21 Per 10-mmHg increase 1.20 (1.06–1.35)
Diastolic blood pressure (mmHg) 82±10 85±11 Per 10-mmHg increase 1.32 (1.05–1.67)
Use of antihypertensive drugs (%) 27 34 Yes vs no 1.00 (0.59–1.68)
WHR 0.92±0.09 0.93±0.08 Per 0.01 increase 1.01 (0.98–1.05)
Waist circumference (cm) 93.5±11.2 97.1±11.0 Per 5-cm increase 1.12 (0.99–1.26)
BMI (kg/m2) 27.0±3.8 28.7±4.7 Per 5-kg/m2 increase 1.36 (1.02–1.83)
Total cholesterol (mmol/l) 6.6±1.2 6.9±1.2 Per 1-mmol/l increase 1.23 (1.02–1.49)
HDL cholesterol (mmol/l) 1.3±0.4 1.3±0.4 Per 0.1-mmol/l increase 1.00 (0.93–1.08)
Triglycerides (mmol/l) 1.5 (1.1–2.1) 2.0 (1.3–2.9) Per 10% increase 1.05 (1.00–1.09)
Homocysteine (μmol/l) 11.4 (9.3–14.1) 11.2 (9.7–14.1) Per 10% increase 1.01 (0.95–1.08)
History of cardiovascular disease (%) 22 28 Yes vs no 1.16 (0.68–1.97)
ACR (mg/mmol) 0.84 (0.58–1.30) 1.07 (0.60–2.58) Per 10% increase 2.01 (1.45–2.79)
Microalbuminuria (%) 10 25 Yes vs no 2.07 (1.11–3.86)
vWf (IU/ml) 1.37±0.71 1.40±0.66 Per 10% increase 0.99 (0.95–1.04)
CRP (mg/l) 1.69 (0.80–3.61) 2.39 (1.16–4.72) Per 10% increase 1.01 (0.99–1.03)
sVCAM-1 (ng/ml) 1298 (1080–1583) 1355 (1157–1669) Per 10% increase 1.02 (0.95–1.10)
sICAM-1 (ng/ml) 462 (370–541) 500 (413–601) Per 10% increase 1.07 (0.99–1.15)
Inflammatory marker z score −0.03±0.77 0.18±0.73 Per 1-unit increase 1.16 (0.88–1.54)
Endothelial function marker z score −0.03±0.57 0.21±1.14 Per 1-unit increase 1.24 (0.90–1.71)
Data are presented as percentages, means±SD or, in the case of a skewed distribution, as medians (interquartile ranges). Odds ratios (OR)
with 95% CIs were obtained by logistic regression after adjustment for age, sex and glucose tolerance status (unless it was the variable
under consideration)
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We tested for interactions of diabetes status (newly dis-
covered and known) with markers of endothelial dysfunc-
tion and inflammation (diabetes yes/no×marker tertile). Data
are presented as odds ratios (ORs) with 95% CIs. All an-
alyses were performed using SPSS statistical software,
Version 10.1 for Windows 95 (SPSS, Chicago, IL, USA). A
p value of less than 0.05 was considered statistically
significant.
Results
Retinopathy was present in 85 (13.6%) of the 625 individ-
uals assessed by funduscopy and/or fundus photography.
Table 1 shows the baseline characteristics of the subjects
according to retinopathy status, and the odds ratios for
retinopathy for each risk factor or risk indicator, adjusted
for age, sex and glucose tolerance status (unless it was the
variable under consideration). Type 2 diabetes, HbA1c, sys-
tolic and diastolic blood pressure, BMI, total cholesterol,
triglycerides and microalbuminuria were significantly asso-
ciated with retinopathy. Among the non-diabetic subjects,
systolic and diastolic blood pressures were significantly
higher in subjects with retinopathy than in those without
retinopathy (p=0.05 and p=0.03, respectively). However,
among the diabetic subjects, only systolic blood pressure
was significantly higher in subjects with retinopathy (p=
0.01) (data not shown).
Levels of CRP, sICAM-1, vWf and sVCAM-1 were
weakly correlated with each other. The age-, sex- and
glucose-tolerance-adjusted correlation coefficient between
sICAM-1 and sVCAM-1 was 0.31 (p<0.001); all other
factors were less strongly correlated (data not shown).
The prevalence of retinopathy increased across increas-
ing tertiles of CRP and sICAM-1 (Fig. 1). The highest
tertiles of CRP and sICAM-1 were both associated with
retinopathy, with non-significant odds ratios of 1.7 (p=0.11
and 0.08 respectively) compared with the lowest tertiles,
whereas the highest tertile of the inflammatory marker z
score was significantly associated with retinopathy
(OR=2.2, 95% CI 1.2–4.1, p=0.01), after adjustment for
age, sex and glucose tolerance status (Table 2). These
associations were present in both non-diabetic and diabetic
individuals. Additional adjustment for systolic and diastol-
ic blood pressure, BMI, total cholesterol and triglycerides
did not materially change these results.
There was a significant interaction (p=0.005) between
endothelial dysfunction and diabetes status; thus, the re-
sults are shown separately for individuals with and those
without diabetes. Table 3 shows that, after adjustment for
sex and age, the highest tertile of the endothelial dysfunc-
tion marker z score was significantly associated with ret-
inopathy among diabetic subjects (OR=4.4, 95% CI 1.2–
15.9, p= 0.02) but not among non-diabetic subjects (OR=
0.5, 95% CI 0.2–1.3, p=0.17). The highest tertile of
sVCAM-1 was also significantly associated with retinop-
athy in diabetic subjects (OR=4.5, 95% CI 1.4–14.3,
p=0.01), whereas the highest tertiles of vWf and ACR
were associated with a non-significant elevated risk of
retinopathy among diaLbetic subjects (p=0.08 and 0.46,
respectively). Additional adjustment for systolic and dias-
tolic blood pressure, BMI, total cholesterol and triglycer-
ides did not considerably change these associations.
Additional analyses It has been argued that sVCAM-1 may
also be considered an indicator of inflammation and
sICAM-1 an indicator of endothelial dysfunction. How-
ever, neither the addition of sVCAM-1 to the inflamma-
tory marker z score nor the addition of sICAM-1 to the
endothelial dysfunction marker z score altered the results
(data not shown).
In addition, the values for the association between the
endothelial dysfunction marker z score and retinopathy
Fig. 1 Prevalence of retinopathy according to tertiles (low, white
bars; medium, hatched bars; high, black bars) of CRP, sICAM-1,
vWf, sVCAM-1 and ACR. *p<0.05 for trend
Table 2 Odds ratios (95% CIs)
for retinopathy associated with
markers of inflammation in all
subjects
aAdjusted for age, sex and glu-
cose tolerance status; bas crude
model with additional adjust-
ment for systolic and diastolic
blood pressure, BMI, total cho-
lesterol and triglycerides; cz
score for CRP+sICAM-1. n/N,
number of cases/total number
Crude modela Adjusted modelb
Tertiles n/Nc OR (95% CI) OR (95% CI)
CRP (mg/l) 0.02–1.10 19/203 1 1
1.11–2.84 28/201 1.32 (0.70–2.49) 1.21 (0.64–2.31)
2.85–35.18 37/200 1.66 (0.89–3.08) 1.41 (0.75–2.68)
sICAM-1 (ng/ml) 97.2–410.2 20/200 1 1
410.4–512.7 26/201 1.17 (0.62–2.20) 1.19 (0.63–2.24)
512.8–1793.6 37/201 1.71 (0.94–3.11) 1.50 (0.81–2.75)
Inflammatory marker z scorec −1.35 to −0.39 17/200 1 1
−0.38 to 0.09 25/201 1.40 (0.72–2.70) 1.32 (0.68–2.58)
0.10 to 4.90 41/201 2.22 (1.19–4.12) 1.96 (1.03–3.72)
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were adjusted for the inflammatory marker z score and
vice versa. Neither adjustment altered the results presented
above (data not shown).
Values were also adjusted for prior cardiovascular
disease, HbA1c, and antihypertensive treatment (data not
shown). Adjustment for HbA1c reduced the odds ratio for
the highest tertile of the inflammatory marker z score to
1.8 (95% CI 0.9–3.3), and the odds ratios for the endo-
thelial function marker z score were 0.4 (95% CI 0.2–1.2)
and 4.45 (95% CI 1.13–17.60) in non-diabetic and diabetic
subjects, respectively. Furthermore, additional adjustment
for prior CVD and anti-hypertensive treatment did not
change the results (p>0.05 for the summarised scores for
inflammation and endothelial dysfunction).
Discussion
In the present study, inflammatory activity was associated
with retinopathy in both diabetic and non-diabetic indi-
viduals, and endothelial dysfunction was associated with
retinopathy in diabetic individuals, but not in non-diabetic
individuals. These associations were independent of other
risk factors for retinopathy and of each other, and suggest
the involvement of inflammatory processes and endothelial
dysfunction in the pathogenesis of this complication.
This is the first population-based study to show that
inflammatory activity, estimated by a z score for CRP and
sICAM-1, is associated with retinopathy in diabetic indi-
viduals, as well as in non-diabetic individuals. In previous
studies, inflammation has been shown to play an important
role in atherosclerosis [26]. Inflammatory activity is higher
in individuals with type 1 or type 2 diabetes than in their
non-diabetic peers [9, 27], and inflammatory activity in di-
abetes is associated with macrovascular disease [5, 6, 9, 11,
22, 28, 29] and microangiopathy [11, 15, 30]. Our data are
consistent with these results, and show that inflammatory
activity may also be important in the pathogenesis of ret-
inopathy in non-diabetic individuals.
Endothelial dysfunction was associated with a 5-fold
higher risk of retinopathy in diabetic subjects; there was no
clear association in non-diabetic subjects. It has been
hypothesised that endothelial dysfunction is a key feature
of the pathogenesis of atherosclerosis in diabetic and non-
diabetic individuals [26, 31] and also of the pathogenesis of
diabetic microangiopathy, especially nephropathy [4, 10,
11, 32]. However, relatively few studies have reported on
the association between markers of endothelial function
and retinopathy. Individuals with diabetic retinopathy (type
1 and type 2) have been shown to have higher levels of
sVCAM-1 than those without retinopathy [15–17]. Results
on the relationship between vWf and retinopathy have been
conflicting. On the one hand, in early-stage retinopathy in
type 1 diabetes, vWf has been associated with a prolonged
retinal circulation time and reduced retinal blood flow,
which may promote stasis in the retinal circulation, leading
to hypoxaemia [33]. On the other hand, vWf was not found
to be related to the presence and development of very early
retinopathy in type 1 diabetes [34]. Microalbuminuria isTa
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often regarded as a marker of generalised endothelial dys-
function [4], and is strongly associated with retinopathy in
both type 1 and type 2 diabetes [12–14]. Microalbuminuria
was also strongly associated with retinopathy in our study.
However, within the normal range, tertiles of ACR were
not strongly associated with retinopathy. Taken together,
the results of previous work and the present study are con-
sistent with a role for endothelial dysfunction in the path-
ogenesis of diabetic retinopathy. Although associations
with individual markers (vWf, sVCAM-1, ACR) have not
always been consistent, this may partly be due to the con-
siderable biological variation inherent in the (usually sin-
gle) measurement of such markers. A major advantage of
the use of an endothelial function marker z score is that it
limits the influence of biological variation, giving a more
precise estimate. Indeed, our data suggest that the asso-
ciation between endothelial dysfunction and retinopathy in
type 2 diabetes is relatively strong.
Changes in the retina, similar to those that occur in
diabetic retinopathy, can also be found in non-diabetic
individuals [1, 35, 36], although such changes do not reach
the stage of diabetic macular oedema or proliferative reti-
nopathy. Risk factors for these early phases of retinopathy
in non-diabetic subjects were hypertension, IGT status, dys-
lipidaemia and obesity [1, 35]. The present results indicate
that inflammatory activity may also contribute to these early
phases.
Our results are supported by recent experimental studies,
mainly on rodent retinas, which have shown that retinop-
athy is associated with low-grade chronic inflammation
[37, 38]. It has been hypothesised that vascular endothelial
growth factor (VEGF), a molecule closely related to the
pathogenesis of retinopathy, can trigger early retinal in-
flammation by inducing the expression and upregulation of
sICAM-1 [39]. Increased levels of adhesion molecules,
which cause leucocyte adhesion and stasis in the retinal
vasculature [40, 41], and increased permeability of the
endothelium, may be the initial step in the complex pa-
thology of retinopathy [42]. Leucostasis could produce tem-
porary ischaemia upstream and subsequent reperfusion,
which may lead to endothelial cell injury and death through
the formation of reactive oxygen species [43].
The associations of inflammation and endothelial dys-
function with retinopathy were independent of each other,
suggesting that inflammation and endothelial dysfunction
play separate roles in the pathogenesis of retinopathy.
Because of the cross-sectional design of this study, it does
not provide information on the inter-relationship between
inflammation and endothelial dysfunction, except that ad-
hesion molecules were weakly correlated. Nevertheless, ex-
perimental evidence and observational data in humans show
that inflammation can induce endothelial dysfunction and
vice versa, thus potentially creating a vicious circle [11].
One of the strengths of this study was that we inves-
tigated several markers of inflammation and endothelial
dysfunction simultaneously.We created z scores, producing
statistically robust summarising estimates of both inflam-
mation and endothelial dysfunction. Inflammation and en-
dothelial dysfunction are complex entities that cannot be
accurately reflected by a single marker. Since sICAM-1
and sVCAM-1 both contribute to leucocyte adhesion and
transmigration through the endothelium following activation
in response to inflammatory cytokines [44, 45], sICAM-1
and sVCAM-1 may be markers of both inflammation and
endothelial dysfunction. For this reason, we constructed
two summarising scores for inflammation, one with and one
without sVCAM-1, and two summarizing scores for endo-
thelial dysfunction, one with and one without sICAM-1.
This did not materially change the results.
A main limitation of this study was the relatively small
sample size, which resulted in wide confidence intervals.
Furthermore, this power problem prevented the stratifica-
tion of the subjects according to different stages of reti-
nopathy. The majority of individuals with retinopathy had
minimal non-proliferative retinopathy (n=73), indicating
that inflammatory activity and endothelial dysfunction are
involved in even minimal disorders of the retinal vascu-
lature. The associations were, if anything, stronger in the
small group of participants (n=12) with worse than min-
imal non-proliferative retinopathy (data not shown).
We conclude that inflammatory activity and endothelial
dysfunction are potentially important contributors to ret-
inopathy. These data provide a basis for testing the effects
of treatment aimed at decreasing inflammatory activity and
improving endothelial function as a means of preventing or
limiting the progression of retinopathy.
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